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 Abstract 35 
Preclinical studies support a critical role of 5-HT4 receptors (5-HT4Rs) in depression 36 
and anxiety, but their influence in depression- and anxiety-like behaviours and the 37 
effects of antidepressants remain partly unknown. We evaluated 5-HT4R knockout (KO) 38 
mice in different anxiety and depression paradigms and mRNA expression of some 39 
neuroplasticity markers (BDNF, trkB and Arc) and the functionality of 5-HT1AR. 40 
Moreover, the implication of 5-HT4Rs in the behavioural and molecular effects of 41 
chronically administered fluoxetine was assessed in naïve and olfactory bulbectomized 42 
mice (OBX) of both genotypes. 5-HT4R KO mice displayed few specific behavioural 43 
impairments including reduced central activity in the open-field (anxiety), and 44 
decreased sucrose consumption and nesting behaviour (anhedonia). In these mice, we 45 
measured increased levels of BDNF and Arc mRNA and reduced levels of trkB mRNA 46 
in the hippocampus, and a desensitization of 5-HT1A autoreceptors. Chronic 47 
administration of fluoxetine elicited similar behavioural effects in WT and 5-HT4R KO 48 
mice on anxiety-and depression-related tests. Following OBX, locomotor hyperactivity 49 
and anxiety were similar in both genotypes. Interestingly, chronic fluoxetine failed to 50 
reverse this OBX-induced syndrome in 5-HT4R KO mice, a response associated with 51 
differential effects in hippocampal neuroplasticity biomarkers. Fluoxetine reduced 52 
hippocampal Arc and BDNF mRNA expressions in WT but not 5-HT4R KO mice 53 
subjected to OBX. These results demonstrate that the absence of 5-HT4Rs triggers 54 
adaptive changes that could maintain emotional states, and that the behavioural and 55 
molecular effects of fluoxetine under pathological depression appear to be critically 56 
dependent on 5-HT4Rs.  57 
 58 
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1. Introduction   65 
Depression is one of the most prevalent major neuropsychiatric diseases, affecting 20% 66 
of the population (Hirschfeld, 2012). Dysfunctions in brain serotonin (5-67 
hydroxytryptamine, 5-HT) volume transmission (Descarries et al., 1975) are postulated 68 
to be the major basis of depression, but also of almost all mental diseases (Sharp et al., 69 
2007). During the last two decades, studies have mainly investigated the role of the 5-70 
HT1 and 5-HT2 receptors but, recently, the 5-HT4 receptors (5-HT4Rs) have taken place 71 
in this scenario (Conductier et al., 2006; Lucas et al., 2007). Analyses in postmortem 72 
brain samples from depressed subjects showed a greater density and functionality of 5-73 
HT4Rs in cortical and striatal areas (Rosel et al., 2004). Moreover, in vivo PET imaging 74 
studies in humans demonstrated that a reduction in 5-HT4Rs potential binding in the 75 
striatum is associated with a high risk to suffer from major depression (Madsen et al., 76 
2014). Conversely, a moderate reduction in the concentration of 5-HT4Rs in both the 77 
striatum and amygdala was described in patients treated with fluoxetine for three weeks 78 
(Haahr et al., 2014). From the preclinical approach, two different animal models of 79 
depression, olfactory bulbectomised (OBX) and glucocorticoid heterozygous receptor 80 
mice, showed an increase in the expression of 5-HT4Rs in the ventral hippocampus or 81 
striatum, respectively (Licht et al., 2010). In contrast, a down-regulation of 5-HT4Rs in 82 
the ventral and dorsal hippocampus was reported in the Flinders-sensitive line rat model 83 
of depression (Licht et al., 2009).  84 
The 5-HT4Rs are implicated in the mechanism of action of antidepressants (Lucas et al., 85 
2007; Vidal et al., 2014). We have previously reported a down-regulation of 5-HT4Rs in 86 
the striatum and hippocampus of rats chronically treated with fluoxetine (Vidal et al., 87 
2009) and venlafaxine (Vidal et al., 2010). A recent study further described that 88 
activation of the 5-HT4Rs may partly mediate some antidepressant and anxiolytic 89 
actions of fluoxetine in predictive behavioural paradigms [tail suspension test (TST) for 90 
depression and open-field/elevated plus maze tests for anxiety (Mendez-David et al., 91 
2014)]. In this context, it is noteworthy to mention that some of the neurogenic actions 92 
induced by selective serotonin reuptake inhibitors (SSRIs) involve the 5-HT4Rs (Imoto 93 
et al., 2015). Interestingly at a clinical level, a short-term treatment with a 5-HT4R 94 
agonist in rats and long-term administration of SSRIs induced similar 95 
antidepressant/anxiolytic actions (Lucas et al., 2007; Pascual-Brazo et al., 2012;  96 
Tamburella et al., 2009; Vidal et al., 2014), a behavioural outcome that is associated 97 
with an increased hippocampal proliferation and neural plasticity markers (Pascual-98 
Brazo et al., 2012).  99 
The anatomical localization of 5-HT4Rs in the brain supports their involvement in 100 
depression and anxiety. These receptors are located in different cerebral structures of 101 
the limbic system (olfactory tubercles, prefrontal cortex, hippocampus, amygdala, shell 102 
of the nucleus accumbens), the basal ganglia including the substantia nigra (Compan et 103 
al., 1996; Waeber et al., 1994), where they modulate the release of different 104 
neurotransmitters, including acetylcholine, 5-HT, GABA and dopamine (reviewed in 105 
Bockaert et al., 2011). Indeed, the 5-HT4Rs located in the medial prefrontal cortex exert 106 
a positive feedback on the firing activity of the dorsal raphe nucleus (DRN) 5-HT 107 
neurons (Lucas and Debonnel, 2002; Lucas et al., 2005), the major origin of 5-HT 108 
projections and whose activity is admitted to be critical for maintaining a homeostatic 109 
brain serotonergic activity. Pharmacological studies have demonstrated that activation 110 
of 5-HT4Rs by selective agonists enhances the electrical activity of the DRN 5-HT 111 
neurons and, interestingly, chronic administration of 5-HT4R agonists does not induce 112 
receptor desensitization in the medial prefrontal cortex (Lucas et al., 2005).  113 
Despite these accumulating evidences about the implication of 5-HT4Rs in depression 114 
and in the effects of antidepressants, few studies have investigated the behavioural, 115 
neurochemical and/or molecular consequences of the genetic ablation of 5-HT4Rs. A 116 
reduced firing (-50%) of the DRN 5-HT neurons, with changes in both the expression of 117 
the 5-HT1ARs in the DRN and hippocampus and increased levels of the 5-HT 118 
transporter (SERT) and mRNA have been reported in 5-HT4R KO mice (Conductier et 119 
al., 2006). Behavioural studies have shown that these mice display abnormal feeding, 120 
locomotor and anxiety-like behaviour in response to stress and novelty, seizure 121 
susceptibility and long-term memory deficits (Compan et al., 2004; Jean et al., 2007; 122 
Jean et al., 2012; Segu et al., 2010). However, whether the 5-HT4R KO mice display 123 
specific anxiety- and depression-like behaviours in different contextual situations (e.g. 124 
novelty suppressed feeding paradigm as a conflict-based test, forced swimming test as a 125 
behavioural despair situation, and chronic depression/anxiety models) remains to be 126 
fully explored. Similarly, little is known about possible adaptive changes in brain 127 
neuroplasticity and neurogenesis in the absence of 5-HT4Rs despite some 128 
pharmacological evidences (Imoto et al., 2015; Pascual-Brazo et al., 2012). In this 129 
context, brain-derived neurotrophic factor (BDNF)/trkB signalling pathway intervenes 130 
in the physiopathology and treatment of mood disorders, as evidenced by clinical and 131 
preclinical studies (Castrén and Rantamäki, 2010; Duman and Monteggia, 2006). 132 
Animals display increased levels of BDNF following electroconvulsive shock and 133 
treatment with classic antidepressant drugs (Balu et al., 2008; Chen et al., 2001; Nibuya 134 
et al., 1995), but also when treated with 5-HT4R agonists (Pascual-Brazo et al., 2012). 135 
The activity-regulated cytoskeleton associated protein (Arc), and other neuroplasticity 136 
markers related to dendritic spine density (Peebles et al., 2010), has also been related to 137 
depression and antidepressant drug treatments (De Foubert et al., 2004; Li et al., 2015).  138 
Here, we suspected that mice lacking the 5-HT4Rs could display a depressive- and 139 
anxiety-like behaviours, especially in environmental challenges and when subjected to 140 
animal models of chronic depression and anxiety. Also we hypothesize that they will 141 
show resistance to the behavioural and molecular effects of antidepressants. Therefore, 142 
we have performed several behavioural analyses, including fluoxetine treatment in 143 
OBX, animal model of chronic depression/anxiety (Linge et al., 2013; Song and 144 
Leonard, 2005), in mice lacking 5-HT4Rs. In addition, the functionality of 5-HT1AR was 145 
evaluated using in vivo and in vitro techniques because the efficacy of chronic 146 
antidepressants is 5-HT1AR-dependent (Albert, 2012). Finally, we have extended our 147 
analyses by in situ hybridization of the BNDF, trkB and Arc mRNA, and hippocampal 148 
proliferation. 149 
 150 
2. Material and Methods  151 
2.1. Animals and experimental groups 152 
The 5-HT4R KO and wild-type (WT) mice (3 months old, 25 ± 1 g) from the breeding 153 
of 5-HT4R heterozygote 129SvTer mice (Compan et al., 2004) or 5-HT4R KO mice 154 
crossed were housed (n = 4-5 per cage) in the animal house of the University of 155 
Cantabria in a temperature – controlled environment with 12 h light/dark cycle, with 156 
food and water available ad libitum. All experiments were carried out with the approval 157 
of the Animal Care Committee of the Universidad de Cantabria and were performed 158 
following the Spanish legislation (Real Decreto 53/2013) and the European 159 
Communities Council Directive 2010/63/UE on “Protection of Animals Used in 160 
Experimental and Other Scientific Purposes”. Before the initiation of the behavioural 161 
studies, 5-HT4R stimulated adenylate cyclase assays were performed to ensure the lack 162 
of functional 5-HT4Rs in KO mice (see methods and Fig. S1).  163 
Three different sets of animals were used (Fig. S2). The first set of WT and 5-HT4R KO 164 
mice were subjected to a battery of anxiety and depression-related tests following a 165 
time-schedule (Fig. S2); then, they were sacrificed and their brains used for the in vitro 166 
studies ([35S]GTPγS autoradiography of 5-HT1AR, in situ hybridization of BDNF, trkB 167 
and Arc, and BrdU immunohistochemistry).  168 
The second set of WT and 5-HT4R KO mice were chronically administered fluoxetine 169 
(160 mg/l in the drinking water, equivalent to 25 mg/kg/day) or vehicle (drinking water) 170 
for 14 days and tested in the same battery of anxiety and depression-related tests. 171 
The third set of WT and 5-HT4R KO mice were subjected to bilateral olfactory 172 
bulbectomy (OBX) or sham surgery using procedures previously employed in our 173 
studies [(Linge et al., 2013; Linge et al., 2016), supplementary material]. After a 4-174 
weeks recovery period, sham and OBX were tested in the open-field to confirm the 175 
development of the typical OBX-induced syndrome. Then, OBX mice of both 176 
genotypes were administered fluoxetine (160 mg/l in the drinking water, equivalent to 177 
25 mg/kg/day) or vehicle (drinking water) and tested in the open-field at day 14 and 28 178 
of treatment.  Finally, they were sacrificed and their brains used for in situ hybridization 179 
of BDNF, trkB and Arc. 180 
2.2. Anxiety and depression tests 181 
Behavioural studies were performed during the light phase, as previously described in 182 
detail (Linge et al., 2016). WT and 5-HT4R KO mice were placed in the experimental 183 
room 30 min before the start of each experiment to acclimatize with the exception of the 184 
nesting test that was performed during the dark phase with mice placed individually for 185 
the session. Behavioural tests were ordered from the least to most stressful one, and 186 
leaving an interval between them (usually 2-3 days) to minimize any potential order 187 
effects [open-field, light-dark box, sucrose intake, novelty suppressed feeding (NSF) 188 
and forced swimming tests (FST)]. Protocols of each test and behavioural testing 189 
schedules are described in detail in the supplementary material. 190 
The open-field test was conducted as previously described (Linge et al., 2013; Linge et 191 
al., 2016) in order to evaluate the motor reactivity to novelty and anxiety-related 192 
parameters (time and distance travelled in the central area).  193 
The light-dark box test was performed as previously described (Clément et al., 2009). 194 
Each mouse was initially placed on the dark side of the box and the time and number of 195 
entries into each zone were recorded and analysed during 5 min. 196 
The sucrose intake test that represents an “hedonic” index, was performed as previously 197 
described (Linge et al., 2016). Mice were deprived of any drink solution for 24 h. The 198 
next day, we quantified the amount of consumed sucrose solution (1%) by each animal 199 
during 1 h. 200 
The nesting test was performed as previously reported (Deacon, 2006), which evaluates 201 
an apathetic and self-neglect behaviour (Pedersen et al., 2014). At the beginning of the 202 
dark phase, mice were individually housed and a 3 g piece of cotton was placed inside 203 
the cage. The next day, a blind and trained observer scored the nest production 204 
according to a 1 to 5 points scale.  205 
The NSF was performed as previously described (Linge et al., 2013). The latency (in 206 
seconds) to eat a pellet placed in the centre of the open-field was evaluated following 24 207 
h food deprivation. Food consumption was also evaluated in mice´s home-cages 208 
(immediately after the NSF test).  209 
The FST permits us to  evaluate behavioural despair, as previously described (Porsolt et 210 
al., 1977). A blind and trained observer manually scored three behavioural parameters 211 
(immobility, swimming, climbing) on video-recorded sessions.  212 
2.3. 8-OH-DPAT-induced hypothermia in mice 213 
The protocol was adapted from Zazpe et al., (2006). The experiments were carried out 214 
in a room equipped with a thermostat (21.0 ± 0.5oC) between 10:00 am and 14:00 pm. 215 
The body temperature was evaluated for a period of 15 s, or until a stable reading was 216 
obtained, by inserting a thermoelectric probe into the rectum (room temperature of 20.0 217 
± 0.1°C). Initially, three measurements were made at 20 min intervals considering the 218 
average of the last two determinations as basal temperature value. Then, 8-OH-DPAT (1 219 
mg/kg) was injected intraperitoneally and the body temperature was evaluated at 20 220 
min.  221 
2.4. In situ hybridization 222 
The brains of mice were rapidly removed and frozen immediately on dry ice and then 223 
stored at -80°C until sectioning. Coronal brain 14 µm thick sections from WT and 5-224 
HT4R KO mice were cut at -20°C using a microtome cryostat and thaw-mounted in 225 
slices and stored at -20°C (for [35S]GTPγS binding assay) or -80°C (for in situ 226 
hybridization). 227 
The protocol was adapted from Castro (Castro et al., 2003a), using oligonucleotides 228 
complementary to BDNF mRNAs 5'-229 
GGTCTCGTAGAAATATTGGTTCAGTTGGCCTTTTGATACCGGGAC-3' (Vaidya 230 
et al., 2001) and trkB mRNAs 5´-231 
CCTTTCATGCCAAACTTGGAATGTCTCGCCAACTTG- 3’ (Madhav et al., 2001) 232 
and Arc 5’-GCAGCTTCAGGAGAAGAGAGGATGGTGCTGGTGCTGG-3’ (Kelly et 233 
al., 2008) were 3´end-labelled with [35S]dATP using terminal deoxynucleotide 234 
transferase. Finally, 250000 c.p.m./slide were mixed with hybridization buffer and 235 
incubated with brain sections (supplementary materials). The specific distribution of 236 
mRNA encoding trkB receptors and BDNF and Arc in the whole brain was consistent 237 
with previous studies (Kelly et al., 2008; Madhav et al., 2001; Vaidya et al., 2001).  238 
2.5. [35S]GTPγS autoradiography of 5-HT1AR 239 
Labelling of brain sections (obtained as described above, see 2.4.) with [35S]GTPγS was 240 
carried out as previously described (Castro et al., 2003b) in order to evaluate the 241 
functionality of 5-HT1AR, using the selective agonist 8-OH-DPAT (10 µM). The non-242 
specific binding was determined in the presence of 10 μM guanosine-5-O-(3-243 
thio)triphosphate (GTPγS, supplementary material). 244 
Labelling of coronal brain sections visualized on autoradiograms were analysed and 245 
quantified ([35S]GTPγS binding) or semi-quantified (in situ hybridization) using a 246 
computerized image analysis Scion Image software (Scion Corporation, MD, USA). 247 
Optical density values were calibrated using 14C microscales, and expressed in nCi/g of 248 
estimated tissue equivalent.  249 
2.6. BrdU-immunohystochemistry 250 
BrdU staining was performed as previously described (Mostany et al., 2008). Free 251 
floating coronal sections were incubated 2 h in 50% formamide/2x SSC (saline sodium 252 
citrate) buffer at 65°C, 30 min in 2N HCl, and 10 min in 0.1M borate buffer. After PBS 253 
washing, sections were incubated in 1% H2O2 for 30 min, blocked 30 min in PBS/0.2% 254 
Triton X-100/5% goat serum and incubated with monoclonal mouse anti-BrdU 255 
overnight at 4°C. After PBS-TS washes, sections were incubated 2 h with biotinylated 256 
goat anti-mouse Fab Fragment IgG secondary antibody, followed by amplification with 257 
avidin-biotin complex (Vector Laboratories). BrdU+ cells were counted using a light 258 
microscope (Carl Zeiss Axioskop 2 Plus) (see supplementary material). 259 
2.7. Drugs and chemicals 260 
[35S]dATP(2’ Deoxyadenosine 5’-(α- thio) Triphosphate, [35S] Guanosine 5’-(γ- thio) 261 
Triphosphate (GTPγS), at a specific activity of 1250 Ci/mmol was purchased from 262 
Perkin Elmer. Zacopride hydrochloride and fluoxetine hydrochloride were purchased 263 
from Tocris Bioscience, and 8-OH-DPAT from Sigma Aldrich. All other chemicals 264 
used were of analytical grade.  265 
2.8. Data analysis and statistics 266 
The statistical analyses were performed using Student’s t-test, Mann-Whitney U test or 267 
two-way ANOVA. When effects of independent variables (treatment, genotype), or 268 
interactions were significant, one-way ANOVAs (treatment, genotype) were performed 269 
followed by post-hoc test when appropriated. The type of statistical analysis is indicated 270 
in the results section and in the legends of figures. The level of significance was set at p 271 
< 0.05 (Table S1). Graphs editing and statistical analyses were performed using the 272 
GraphPad Prism Software (GraphPad, San Diego, CA, USA). 273 
 274 
3. Results 275 
3.1. 5-HT4R KO mice display anhedonia and a context-dependent anxiety-like response 276 
In the open-field test, 5-HT4R KO mice presented lower central activity as evidenced by 277 
a reduction in the central time (46.7 ± 3.0 s) compared with WT counterparts (60.4 ± 5.5 278 
s, p < 0.05, Fig. 1A), with a similar number of entries in the central area (WT: 28.4 ± 279 
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1.5 vs KO: 24.0 ± 1.9, Fig. 1B). It was not associated with altered locomotion because 280 
mice of both genotypes travelled a similar total distance (WT: 20.7 ± 1.5 m vs KO: 21.4 281 
± 0.9 m, Fig. 1C). No difference between the mice of both genotypes was also observed 282 
in the LDB (Fig. 1D). Two-weeks treatment with fluoxetine induced a significant 283 
reduction of the central time in mice of both genotypes (WT-flx: 35.1 ± 4.6 s vs WT, p 284 
< 0.01; KO-flx: 24.9 ± 6.7 s vs KO, p < 0.01, Fig. 1A). Accompanied with a significant 285 
reduction of the central entries (WT-flx: 17.0 ± 2.0 vs WT, p < 0.01; KO-flx: 12.9 ± 2.6 286 
vs KO, p < 0.01, Fig. 1B) but no change was observed in the LDB (Fig. 1D).  287 
Additionally, 5-HT4R KO mice did not show significant changes in the latency to feed 288 
following the NSF test (WT: 203.9 ± 35.6 s vs KO: 219.7 ± 29.8 s, Fig. 1E). Chronic 289 
treatment with fluoxetine induced a similar reduction of the latency to feed in mice of 290 
both genotypes (WT-flx: 102.4 ± 11.4 vs WT, p < 0.05; KO-flx: 118.3 ± 17.9 s vs KO, p 291 
< 0.05, Fig. 1E). Mice of both genotypes consumed a similar amount of food when 292 
returned to the home-cage after the NSF test in the basal conditions and following 293 
chronic fluoxetine treatment (Fig. 1F).  294 
 295 
 296 
 297 
Figure 1. Behaviour of WT and 5-HT4R KO mice in different anxiety-related 298 
paradigms. In the open-field test (5 min), 5-HT4R KO mice spent less time than WT 299 
counterparts in the central zone, and chronic fluoxetine induced a significant reduction 300 
of the central time spent in mice of both genotypes (A). WT and 5-HT4R KO exhibited 301 
a similar number of central entries, and chronic fluoxetine induced a similar effect in 302 
mice of both genotypes (B). Total distance was not significantly different between mice 303 
of both genotypes and following fluoxetine treatment (C). No significant changes were 304 
found in the light-dark box test. (D) The latency to feed between WT and 5-HT4R KO 305 
mice was not different, and a similar reduction was found in mice of both genotypes 306 
following the chronic fluoxetine treatment (E). Post-NSF test food intake was not 307 
different between mice of both genotypes and following fluoxetine treatment (F). Data 308 
are mean ± SEM of n = 13-18 mice per group. Two-way ANOVA revealed a main 309 
effect of the genotype and treatment on the time spent in the central part of the open-310 
field (F(1,58) = 6.0, p < 0.05 for genotype effect and F(1,58) = 23.2, p < 0.001 for treatment 311 
effect) (A). Also, a main effect of the genotype (F(1,58) = 5.1, p < 0.05) and treatment 312 
(F(1,58) = 34.2, p < 0.001) was found on the number of central entries in the open field 313 
(C) and a treatment effect was found in the latency to feed in the novelty suppressed 314 
feeding (F(1,50) = 14.4, p < 0.001) (E). *p < 0.05 and **p < 0.01 (Newman-Keuls post 315 
hoc test). 316 
 317 
5-HT4R KO animals showed a lower sucrose intake than WT counterparts (KO: 1.5 ± 318 
0.1 ml vs WT: 2.0 ± 0.1 ml, p < 0.001, Fig. 2A), an outcome that was reversed by 319 
chronic fluoxetine (KO-flx: 2.3 ± 0.1 ml vs KO, p < 0.01, Fig. 2A). Additionally, an 320 
impaired nesting performance was observed in 5-HT4 R KO mice (nesting score of KO: 321 
4.1 ± 0.3 vs WT: 4.8 ± 0.1, p < 0.05, Fig. 2B). In the FST, mice of both genotypes 322 
exhibited similar immobility (WT: 206.4 ± 6.2 s vs KO: 204.7 ± 9.1 s, Fig. 2C), 323 
swimming (WT: 30.3 ± 5.4 s vs KO: 33.1 ± 8.5 s, Fig. 2D) and climbing (WT: 3.4 ± 1.1 324 
s vs KO: 2.1 ± 1.1 s, Fig. 2E) scores. Chronic fluoxetine treatment induced similar 325 
reductions in immobility (WT-flx: 161.0 ± 12.0 s vs WT, p < 0.01; KO-flx: 153.3 ± 12.6 326 
s vs KO, p < 0.01, Fig. 2C), and increases in both swimming (WT-flx: 63.9 ± 9.8 s vs 327 
WT, p < 0.05; KO-flx: 76.1 ± 11.1 s vs KO, p < 0.01, Fig. 2D) and climbing (WT-flx: 328 
15.1 ± 3.2 s vs WT, p < 0.001; KO-flx: 11.6 ± 2.4 s vs KO, p < 0.05, Fig. 2E) 329 
behaviours in mice of both genotypes.  330 
 331 
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 333 
Figure 2. Behaviour of WT and 5-HT4R KO mice in different depression-related 334 
paradigms. 5-HT4R KO mice exhibited reduced sucrose intake that was reversed by 335 
chronic fluoxetine treatment (A), and reduced nesting behaviour (B) compared with WT 336 
mice. No differences were observed between mice of both genotypes in all FST 337 
parameters [immobility (C), swimming (D) and climbing (E)]. In the sucrose intake 338 
test, two-way ANOVA analyses revealed a main effect of treatment (F(1,60) = 22.7, p < 339 
0.001), and a main effect of genotype x treatment interaction (F(1,60) = 9.5, p < 0.01). In 340 
the nesting test, two-way ANOVA analysis revealed a main effect of genotype (F(1,63) = 341 
4.4, p < 0.05). In the FST, chronic fluoxetine treatment induced similar effects in all the 342 
measured outcomes in mice of both genotypes; two-way ANOVA analyses revealed a 343 
main effect of treatment (immobility: F(1,51) = 21.6, p < 0.001; swimming: F(1,51) = 18.3, 344 
p < 0.001; climbing: F(1,50) = 20.7, p < 0.001). Data are mean ± SEM of n = 13-20 mice 345 
per group. * p < 0.05, **p < 0.01 and ***p < 0.001 (Newman-Keuls post hoc test). 346 
 347 
3.2. 8-OH-DPAT-induced hypothermia following chronic fluoxetine treatment 348 
The functionality of 5-HT1ARs was assessed in vivo by measuring 8-OH-DPAT-induced 349 
hypothermia (Fig. 3). A similar decrease of rectal temperature in vehicle-treated mice of 350 
both genotypes was observed at 20 min following the administration of 8-OH-DPAT 351 
(WT: -2.9 ± 0.3ºC vs KO: -2.7 ± 0.3ºC). As expected, chronic treatment with fluoxetine 352 
induced a reduction of the hypothermia induced by 8-OH-DPAT administration in mice 353 
of both genotypes (WT- flx: -1.8 ± 0.1ºC vs WT, p < 0.01; KO-flx: -1.1 ± 0.2ºC vs KO, 354 
p < 0.001). This reduction was lower in fluoxetine-treated 5-HT4R KO compared with 355 
fluoxetine-treated WT mice (p < 0.05).  356 
 357 
Figure 3. Effect of chronic administration of fluoxetine on 8-OH-DPAT-induced 358 
hypothermia paradigm. Chronic administration of fluoxetine induced a reduction of the 359 
hypothermic effect of 8-OH-DPAT in mice of both genotypes. Note that 5-HT4R KO 360 
mice treated chronically with fluoxetine exhibited a significant lower 8-OH-DPAT-361 
induced hypothermic effect respect to WT counterparts. Two-way ANOVA analysis 362 
revealed a main effect of the genotype (F(1,19) = 4.7, p < 0.05), treatment (F(1,19 ) = 42.3, 363 
p < 0.001) but not a main effect of the genotype x treatment interaction. Data are mean 364 
± SEM of n = 5-7 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001 (Newman-365 
Keuls post hoc test).  366 
 367 
3.3. Reduced G-protein signalling of presynaptic 5-HT1AR in 5-HT4R KO mice  368 
The 5-HT1AR activity was also assessed in vitro by measuring 8-OH-DPAT stimulated 369 
[35S]GTPγS binding in brain sections from mice of both genotypes. As shown in Table 370 
1 and Fig. 4, 8-OH-DPAT-induced stimulation of specific [35S]GTPγS binding was 371 
lower in the DRN of 5-HT4R KO mice compared with WT counterparts (-28.3%, p < 372 
0.05). An increase in basal [35S]GTPγS binding values (nCi/g tissue) was also detected 373 
in the brain of 5-HT4R KO mice at the level of both the DRN (WT: 301.8 ± 6.8 vs KO: 374 
360.5 ± 19.3, p < 0.05) and the prefrontal cortex (WT: 285.9 ± 25.5 vs KO: 377.8 ± 375 
22.4, p < 0.05). No significant differences were found either in basal and stimulated 376 
[35S]GTPγS binding in the others areas analysed (the hippocampus and entorhinal 377 
cortex). 378 
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Table 1. Absolute values (nCi/g tissue) of specific [35S]GTPγS binding induced by 8-381 
OH-DPAT. DRN: dorsal raphe nucleus, PFrCx: prefrontal cortex, CA1: CA1 field of 382 
the hippocampus, CA3: CA3 field of the hippocampus, DG: dentate gyrus of the 383 
hippocampus and EntCx: entorhinal cortex. Data are mean ± SEM, number of animals 384 
per condition in brackets (n). *p < 0.05 (Student´s t - test, unpaired data). 385 
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 404 
Figure 4. Autoradiographs in transverse midbrain sections of 8-OH-DPAT stimulated 405 
[35S]GTPγS binding. Upper: WT mice, basal (A) and stimulated (A’) binding. Lower: 5-406 
HT4R KO mice, basal (B) and stimulated binding (B’). DRN: dorsal raphe nucleus. 407 
Scale bar = 1 mm. 408 
 409 
3.4. Altered BDNF, trkB and Arc expression levels in 5-HT4R KO mice  410 
Differences between WT and 5-HT4R KO mice were detected in the levels of both 411 
BDNF and trkB mRNA. The highest levels of BDNF and trkB mRNA were observed in 412 
Specific [35S]GTPγS binding induced by 8-OH-DPAT 
(nCi/g tissue) 
Brain areas 
WT 5-HT4R KO 
DRN 181.9 ± 9.7 (7) 130.4 ± 18.3 (7)* 
PFrCx 82.4 ± 17.0 (7) 94.8 ± 19.0  (6) 
CA1 194.7 ± 25.8 (7) 222.8 ± 28.7 (7) 
CA3 68.7 ± 17.5 (5) 69.4 ± 19.6 (6) 
DG 58.8 ± 22.7 (5) 64.4 ± 25.9 (7) 
EntCx 167.5 ± 13.5 (6) 218.5 ± 18.8 (7) 
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the hippocampus of both WT and 5-HT4R KO mice. The 5-HT4R KO mice showed 413 
higher increases in the levels of BDNF mRNA in the dentate gyrus (DG) of the 414 
hippocampus than WT mice (∼35%; p < 0.05, Fig. 5A), which was not associated with 415 
significant changes in the levels of trkB mRNA (Figs. 5B and F). Additionally, 5-HT4R 416 
KO mice exhibited reduced levels of trkB mRNA in the other hippocampal fields (CA1 417 
and CA3: ∼ 15 %, p < 0.01), and in the amygdala (∼ 26 %, p < 0.05) compared with WT 418 
mice (Figs. 5B and F). No differences were detected in the levels of trkB and BDNF 419 
mRNA in the examined areas of the cerebral cortex between mice of both genotypes 420 
(Figs. 5A, B and F). Finally, the levels of mRNA encoding Arc (Figs. 5C and F) were 421 
increased in the CA1 and CA3 hippocampal fields and the cingulate cortex in 5-HT4R 422 
KO mice (∼ 50%) compared with WT mice (p < 0.05). 423 
3.5. Absence of impaired hippocampal proliferation in 5-HT4R KO mice 424 
Hippocampal proliferation was evaluated as the incorporation of the thymidine analogue 425 
BrdU in the subgranular zone of the DG. A similar number of BrdU immunolabelled 426 
cells was detected in both 5-HT4R KO (1522.0 ± 149.3 BrdU+ cells, Fig. 5E) and WT 427 
(1483.0 ± 109.3 BrdU+ cells, Fig. 5D) mice.  428 
 429 
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 447 
Figure 5. Changes in neuroplasticity markers in 5-HT4R KO mice. Levels of BDNF 448 
(A), trkB (B) and Arc (C) mRNA. Data are mean ± SEM, n = 6-7 mice per group. 449 
mPFCx: medial prefrontal cortex, FCx: frontal cortex, Amyg: amygdala, CingCx: 450 
cingulate cortex, CA1 and CA3: CA1 and CA3 fields of the hippocampus and DG: 451 
dentate gyrus. *p < 0.05 and **p < 0.01 vs WT, Student´s t-test, unpaired data. 452 
Illustrations showing BrdU immunopositive cells in the DG in WT (D) and 5-HT4R KO 453 
(E) mice, scale bar: 20 μm. (F) Distribution of BDNF (a, b), trkB (a’, b’) and Arc (a’’, 454 
b’’) mRNA visualized on autoradiographs in transverse brain sections from WT (upper) 455 
and 5-HT4R KO mice (lower) at the level of the dorsal hippocampus, following in situ 456 
hybridization. Scale bar: 2 mm. 457 
3.6. Chronic fluoxetine failed to reverse OBX-induced syndrome in 5-HT4R KO mice  458 
Following four weeks of OBX surgery, mice of both genotypes displayed similar 459 
locomotor hyperactivity, as evidenced by the increased total distance travelled in the 460 
open-field (WT-sham: 18.3 ± 0.9 m vs WT-OBX: 25.4 ± 2.8 m, p < 0.05; KO-sham: 461 
16.7 ± 1.0 m vs KO-OBX: 24.4 ± 3.2 m, p < 0.05, Fig. 6A). A similar temporal pattern 462 
of locomotor activity was observed in mice of both genotypes before and after sham or 463 
OBX surgery (Figs. S3A and B). This hyperactivity was related to an enhanced 464 
thigmotaxis as reflected by an increased ambulation at the periphery of the open-field 465 
(WT-sham: 13.8 ± 1.2 m vs WT-OBX: 23.6 ± 2.7 m, p < 0.05; KO-sham: 12.4 ± 1.2 m 466 
vs KO-OBX: 22.4 ± 3.1 m, p < 0.01) (Fig. S4A). 467 
Mice of both genotypes exhibited similar anxiety-like behaviour induced by OBX, as 468 
evidenced by a reduced activity in the central part of the open-field (central time: WT-469 
sham: 49.8 ± 10.3 s vs WT-OBX: 9.2 ± 1.4 s, p < 0.001; KO-sham: 42.5 ± 6.1 s vs KO-470 
OBX: 13.0 ± 3.0 s, p < 0.001, Fig. 6B). Similar readouts were observed in other central 471 
parameters (Figs. S4B and C). 472 
 473 
Figure 6. Similar responses to olfactory bulbectomy in WT and 5-HT4R KO mice. 474 
Total distance (A) and central time (B) in the open-field following 4 weeks post 475 
surgery. Data represent mean ± SEM of n = 7-8 mice per group. Two-way ANOVA 476 
revealed a main effect of the surgery on the total distance travelled (F(1,26) = 9.4, p < 477 
0.01) and on the time spent in the central part of the open-field (F(1,26) = 35.1, p < 0.001) 478 
but no significant surgery x genotype interaction. *p < 0.05 and ***p < 0.001 479 
(Newman-Keuls post hoc test). 480 
 481 
Considering similarities in OBX-syndrome between both WT and 5-HT4R KO mice, 482 
fluoxetine was chronically administrated for 28 days. Animals were again tested in the 483 
open-field at days 14 and 28 (Fig. 7). A post hoc analysis showed a total reversal of the 484 
OBX-induced hyperactivity in fluoxetine-treated WT-OBX mice. Indeed, chronic 485 
fluoxetine treatment reduced, in a time-dependent manner, the characteristic OBX-486 
induced locomotor hyperactivity to values similar to those observed in the respective 487 
sham-operated mice (WT-OBX-fluoxetine: 10.8 ± 2.4 m vs WT-OBX: 23.6 ± 2.7 m, p < 488 
0.05) following 28 days of treatment. In contrast, chronic administration of fluoxetine 489 
failed to reverse OBX-induced hyperactivity in 5-HT4R KO mice [achieving only 15% 490 
of reduction in the total distance travelled, (Fig. 7A)]. Additionally, chronic 491 
administration of fluoxetine failed in eliciting a positive effect in the habituation to 492 
novelty in 5-HT4R KO mice (Fig. 7B). 493 
 494 
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497 
Figure 7. Chronic fluoxetine failed to reverse OBX syndrome in 5-HT4R KO mice. 498 
Total peripheral distance (OF, 5 min session) evaluated before and following fluoxetine 499 
(flx) treatment; Two-way ANOVA revealed a genotype x time interaction on the 500 
distance travelled at the periphery [F(1,26) = 7.1, p < 0.01 (A)]. Peripheral distance per 501 
one min intervals at day 28 of fluoxetine treatment (flx 28d); Two-way ANOVA 502 
revealed a significant effect of time (F(4,52) = 4.7, p < 0.01) and genotype [F(1,13) = 6.6, p 503 
< 0.05 (B)]. Data are mean ± SEM of n = 7-8 mice per group. #p < 0.05 vs pre-flx; *p < 504 
0.05 and **p < 0.01 vs 1 min intervals (Newman-Keuls post hoc test). Pre-flx: before 505 
the treatment with fluoxetine; flx 14d and flx 28d: 14 and 28 days of fluoxetine 506 
treatment. 507 
 508 
3.7. Differential changes in BDNF and Arc mRNA in chronic fluoxetine-treated 5-HT4R 509 
KO-OBX mice 510 
In order to set out to explore the neural substrates related to the behavioural outcome of 511 
5-HT4R KO-OBX mice chronically treated with fluoxetine, we assayed the levels of 512 
BNDF and Arc mRNA. A differential regulation in plasticity makers was observed 513 
between WT and 5-HT4R KO mice. In WT-OBX mice, the chronic fluoxetine treatment 514 
induced decreases in the levels of BNDF mRNA in the DG (21%, p < 0.05 vs WT-515 
OBX, Fig. 8A) and CA3 (31%, p < 0.05 vs WT-OBX, Fig. 8B) hippocampal areas 516 
examined, but not in 5-HT4R KO-OBX mice. The antidepressant exerted a similar effect 517 
in the levels of BNDF mRNA in CA1 hippocampal field in mice of both genotypes 518 
subjected to OBX (Fig. 8C).  519 
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In addition, chronic fluoxetine treatment induced decreases in the levels of Arc mRNA 520 
in both WT and 5-HT4R KO-OBX mice in the DG (Fig. 8D) and CA3 (Fig. 8E) 521 
hippocampal areas. However, the antidepressant did reduce the levels of Arc mRNA in 522 
the CA1 in WT-OBX (56%, p < 0.01 WT-OBX-FLX vs WT-OBX), but not in 5-HT4R 523 
KO mice (Fig. 8F).  524 
 525 
 526 
Figure 8. mRNA expression of neuroplasticity markers in chronic fluoxetine-527 
treated OBX mice. Levels of BDNF (A, B, C) and Arc (D, E, F) mRNA. Two-way 528 
ANOVA analyses revealed a significant main effect of treatment on the levels of BDNF 529 
mRNA in the DG (F(1,30) = 16.1, p < 0.001) and in the CA3 (F(1,31) = 14.0, p < 0.001) 530 
hippocampal areas. Two-way ANOVA analyses also revealed a significant main effect 531 
of treatment (F(1,31) = 13.9, p < 0.001) and genotype (F(1,31) = 5.9, p < 0.05) on the levels 532 
of Arc mRNA in the CA1 hippocampal field. Data are mean ± SEM of n = 7-8 mice per 533 
group.  *p < 0.05 and **p < 0.01 (Newman-Keuls post hoc test). 534 
 535 
4. Discussion 536 
The present study shows that 5-HT4R KO mice display anhedonia and a context-537 
dependent anxiety-like behaviour, with responses to the OBX syndrome similar as those 538 
detected in WT mice. A critical present finding is the lack of response of 5-HT4R KO 539 
mice to the behavioural and molecular antidepressant effects of fluoxetine in the animal 540 
model of chronic depression/anxiety (e.g. OBX).  541 
Among all tests used to evaluate the potential depressive-like state of the 5-HT4R KO 542 
mice, we detected that these mutant animals consumed less sucrose. It suggests an 543 
anhedonic-like behaviour and a specific involvement of 5-HT4Rs in one of the 544 
behavioural traits of depression-like behaviour, an outcome reversed by 2-weeks 545 
treatment with fluoxetine. Accordingly, the mutant mice exhibited a reduction in the 546 
nesting score, another behavioural outcome that might reflect both apathetic and 547 
anhedonic-like behaviour. However, results in the forced swimming test indicate that 5-548 
HT4R KO mice are not more prone to show higher behavioural despair or learned 549 
helplessness than their WT counterparts. These findings appears to be in disagreement 550 
with the pharmacological studies reporting a reduced forced swimming test immobility 551 
following acute administration of partial 5-HT4R agonists in rats (Lucas et al., 2007). 552 
This could be due to (i) compensatory neuroplasticity processes that may install 553 
gradually over development in the 5-HT4R constitutive KO mice [e.g. adaptive changes 554 
in serotoninergic system (Conductier et al., 2006), present study], (ii) methodological 555 
differences (animal species and different FST protocols) and/or (iii) because RS67333 is 556 
also a partial agonist that could induced different effects depending on the dose used. 557 
All this could contribute to the similar response in the FST and also explain the same 558 
effect of fluoxetine observed in mice of both genotypes in this experimental paradigm 559 
(Cryan et al., 2005). In addition, the differential behaviour of 5-HT4R KO mice in the 560 
FST vs sucrose/nesting paradigms could be explained by the participation of different 561 
brain areas involved in each particular paradigm. In fact, high concentration of 5-HT4Rs 562 
has been detected in the shell of the nucleus accumbens in rats and mice (Compan et al., 563 
1996; Jean et al., 2007). There, they intervene in motivation for foods and influence 564 
reward processes (Jean et al., 2007; Jean et al., 2012) through the activation of the 565 
cAMP/PKA/pCREB pathway (reviewed in Compan et al., 2015). CREB overexpression 566 
in the nucleus accumbens reduces the rewarding effects of sucrose (Barrot et al., 2002). 567 
And, the ability of cocaine to induce CREB phosphorylation is absent in the nucleus 568 
accumbens of the 5-HT4R KO mice (reviewed in Compan et al., 2015), reinforcing the 569 
fact that the absence of 5-HT4R favours an anhedonic behaviour (present study). Also, 570 
rats subjected to maternal deprivation exhibit a strong correlation between 5-HT4Rs 571 
mRNA in the hippocampus and anhedonia-like behaviour (Bai et al., 2014). The 572 
absence of 5-HT4Rs in the nucleus accumbens and the hippocampus may likely account 573 
for anhedonia-like behaviour of 5-HT4R KO mice. Among the different neuroplasticity 574 
markers that have been analysed in the present study, results revealed increased levels 575 
of Arc mRNA in the hippocampus and the cingulate cortex of 5-HT4R KO mice. This 576 
might support their anhedonia since enhanced expression of Arc mRNA in cortical and 577 
hippocampal areas has been described in rodents subjected to social defeat (Coppens et 578 
al., 2011) and chronic unpredictable mild stress  (Boulle et al., 2014). There is also a 579 
reduced concentration in the 5-HT1AR in the dorsal hippocampus of 5-HT4R KO mice 580 
(Conductier et al., 2006). The participation of these hippocampal 5-HT1ARs in 581 
anhedonia and, especially, in the antidepressant effects of fluoxetine must also be 582 
considered. Indeed, they may participate in the anti-anhedonic effect of chronic 583 
treatment with fluoxetine observed in 5-HT4R KO mice.  584 
Depression- and anxiety-like behaviours rarely exist independently, and here, in the 585 
open-field test, 5-HT4R KO mice presented a reduced central time, suggesting an 586 
increased anxiety in good accordance with a previous report (Compan et al., 2004). 587 
However, in other tests, which also permit us to evaluate anxiety-like responses under 588 
different environmental challenges (light-dark box and novelty suppressed feeding), 5-589 
HT4R KO mice exhibited an anxiogenic response similar to that observed in WT mice. 590 
It is well known that different aspects of emotionality are covered by the umbrella term 591 
"anxiety" (File, 1992). This discrepancy between the findings in the open-field versus 592 
the light-dark box/novelty suppressed feeding tests could be explained when 593 
considering the participation of distinct/complementary brain areas that may be 594 
differentially engaged in each particular test and/or the particular profile of fluoxetine´s 595 
effects in anxiety-related paradigm depending on the dose administered (Dulawa et al., 596 
2004). The behavioural findings following chronic fluoxetine treatment accredit this 597 
hypothesis since its chronic administration produced opposite effects in the open-field 598 
and the novelty suppressed feeding. In fact, fluoxetine induced an anxiogenic effect in 599 
the former but a marked anxiolytic effect in the latter test. Moreover, the light-dark box 600 
rather than open-field is a more appropriate approach to assess permanent anxiety [“trait 601 
anxiety”, (File, 1992; Ramos, 2008)], and the novelty suppressed feeding test more 602 
reliable evaluation of the mice´s performance under a conflictive-aversive context 603 
(Belzung and Griebel, 2001). All the above findings suggest that the Htr4 gene deficit 604 
could enhance anxiety state in a context-dependent manner, but not an anxiety trait, as 605 
seen in the 5-HT1AR but opposite to 5-HT1BR KO mice (Malleret et al., 1999; Ramboz 606 
et al., 1998; Zhuang et al., 1999), suggesting a complementary influence of these 5-HT 607 
receptors in regulating the different facets of anxiety.  608 
In order to better understand the behavioural phenotype of 5-HT4R KO mice and their 609 
response to chronic fluoxetine, we assessed the 5-HT1AR functionality by performing in 610 
vivo and in vitro techniques since this receptor subtype may critically intervene in the 611 
efficacy of chronic antidepressant treatments, and in the neurobiology of depression 612 
(Albert, 2012). 613 
Similarly to the behavioural outcomes observed, chronic administration of fluoxetine 614 
induced a desensitization of 5-HT1ARs in both 5-HT4R KO and WT mice, an outcome 615 
already reported in naïve animals treated with this antidepressant (Rainer et al., 2012). 616 
This was evidenced by a reduced 8-OH-DPAT-induced hypothermia, though this effect 617 
was less apparent in 5-HT4R KO mice, suggesting a higher desensitization of 5-HT1ARs. 618 
As discussed below, [35S]GTPγS binding studies demonstrate increased basal binding 619 
accompanied with a reduction in 8-OH-DPAT induced [35S]GTPγS binding in the 620 
dorsal raphe nucleus. These changes related to the functionality of presynaptic 5-621 
HT1ARs, though not discarding other adaptive mechanisms, may underlie this response 622 
of 5-HT4R KO mice in the 8-OH-DPAT-induced hypothermia test after the chronic 623 
antidepressant treatment.   624 
Also, 5-HT4R KO mice showed a decreased 8-OH-DPAT-induced stimulation of 625 
[35S]GTPγS binding, consistently with a reduced concentration of 5-HT1ARs in the DRN 626 
of these mutant mice (Conductier et al., 2006). An increased basal [35S]GTPγS binding 627 
was observed in 5-HT4R KO mice, what might be due to a higher constitutive receptor 628 
activity, including 5-HT1ARs. If this were the case, it could explain the hypersensitivity 629 
of presynaptic 5-HT1ARs, and why citalopram is more efficient to inhibit the firing of 5-630 
HT neurons in 5-HT4R KO mice than in their WT counterparts (Conductier et al., 631 
2006), though this hypothesis requests confirmation. In line with our results in 5-HT4R 632 
KO mice, reduced levels of both presynaptic (DRN) and postsynaptic 5-HT1AR have 633 
been reported in the hippocampus in mice (Conductier et al., 2006), in postmortem brain 634 
samples from patients with depression (Boldrini et al., 2008; López-Figueroa et al., 635 
2004) and in PET studies (Drevets et al., 2000; Drevets et al., 2007; Hirvonen et al., 636 
2008; Meltzer et al., 2004). Animal studies also describe a decline in 5-HT1AR 637 
expression or functionality in different rodent models of depression/anxiety- following 638 
maternal deprivation (Leventopoulos et al., 2009), social defeat (Kieran et al., 2010), 639 
chronic unpredictable stress (Bambico et al., 2009) and chronic corticosterone treatment 640 
(Rainer et al., 2012). Although it deserves further investigation, these changes on 5-641 
HT1AR in the DRN may represent an adaptive response to counterbalance the absence 642 
of the positive 5-HT4Rs feedback on the firing activity of DRN serotonergic neurons 643 
(Conductier et al., 2006; Lucas and Debonnel, 2002; Lucas et al., 2005).  644 
In using the OBX animal model, we further circumvented how the 5-HT4Rs are 645 
potentially involved in some traits of depression- and anxiety-like behaviour, providing 646 
a first series of results. As mentioned above and recall here, OBX mediates a 647 
depressive-like phenotype as well as other behavioural and neurochemical alterations 648 
that can be reversed by chronic antidepressant treatment (Freitas et al., 2013; Linge et 649 
al., 2013 and 2016; Machado et al., 2012; Song and Leonard, 2005). An earlier study 650 
shows an increase in the concentration of 5-HT4Rs in the hippocampus in OBX mice 651 
(Licht et al., 2010). However, our study shows that the constitutive absence of 5-HT4Rs 652 
did not modify the OBX-induced syndrome. In fact, 5-HT4R KO mice presented a 653 
similar behavioural outcome than WT counterparts following OBX (locomotor 654 
hyperactivity and anxiety-like behaviour in the open-field, thus showing the same 655 
susceptibility to the development and manifestations in this animal model of depression.  656 
The major finding of our study is that chronic fluoxetine was not effective in attenuating 657 
OBX-induced hyperactivity in 5-HT4R KO mice, demonstrating its lack of 658 
antidepressant effect since the reversal of OBX-induced hyperactivity is meant to have 659 
high predictive validity (Freitas et al., 2013; Linge et al., 2013 and 2016; Machado et 660 
al., 2012; Song and Leonard, 2005). Consistently with our results, a previous study in 661 
non-transgenic mice (Mendez-David et al., 2014) showed that, following chronic 662 
corticosterone treatment, some anxiolytic/antidepressant effects of fluoxetine are 663 
prevented by chronic administration of a selective 5-HT4Rs antagonist. However, as 664 
stated above, chronic treatment with fluoxetine induced clear behavioural effects not 665 
only in WT but also in 5-HT4R KO mice under basal conditions.  666 
At a molecular level, increased levels of BDNF and Arc mRNA associated with reduced 667 
levels of trkB mRNA in non-OBX 5-HT4R KO mice (basal condition) suggest adaptive 668 
mechanisms that may likely limit major depressive- and anxiety-like behaviour in these 669 
KO mice. Indeed, these molecular factors are well known to influence these behavioural 670 
traits (see reviews by Castrén and Rantamäki, 2010; Li et al., 2015). Following OBX 671 
surgery, 5-HT4R KO mice treated with fluoxetine did not show the same regulation than 672 
WT counterparts in BDNF and Arc expression in the hippocampus.  The differences in 673 
both the BDNF and Arc mRNA expression detected in the hippocampus of mice of both 674 
genotypes could partly underlie the absence of efficacy of fluoxetine in modifying 675 
locomotion in OBX-5-HT4R KO mice (present study). Consistently, Freitas et al. (2013) 676 
reported that the behavioural effects of chronic fluoxetine in OBX female Swiss mice, 677 
are associated with molecular changes (regulation of ERK1/CREB/BDNF) in the 678 
hippocampus. Our results suggest that the 5-HT4Rs control of both the BDNF mRNA 679 
expression in the DG, and CA3, and Arc mRNA expression in the CA1 can be 680 
implicated in these molecular substrates, which can favor the antidepressant effect of 681 
fluoxetine. Indeed, Imoto et al. (2015), using 5-HT4R KO mice, introduced a potential 682 
role of the 5-HT4Rs in chronic fluoxetine treatment-induced neurogenic activity and 683 
granule cell dematuration in the DG.  684 
Both BDNF and its trkB receptor are implicated in mood disorders (Duman and 685 
Monteggia, 2006). Decreased levels of BDNF and trkB mRNA are observed in the 686 
hippocampus and frontal cortex in postmortem brain samples from patients with 687 
depression (Dwivedi et al., 2003; Thompson et al., 2011), and a positive correlation 688 
between BDNF serum levels and antidepressant responses was reported in individuals 689 
with depression (Brunoni et al., 2008; Sen et al., 2008). Accordingly, chronic stress, a 690 
risk factor of major depression, induced a decrease in the expression of BDNF in the 691 
hippocampus in animals (Smith et al., 1995). A decreased expression of hippocampal 692 
BDNF has been described in the OBX mouse model (Nakagawasai et al., 2016). In 693 
contrast, chronic antidepressant treatments (fluoxetine, reboxetine) provoked increases 694 
in the levels of BDNF in the hippocampus (Baj et al., 2012). Moreover, BDNF mimics 695 
antidepressant-like effects in several behavioural experimental paradigms (Grønli et al., 696 
2006; Murakami et al., 2005). However, the implication of BDNF in anxiety- and 697 
depressive-like behaviour is complex and can be contradictory. For instance, reduced 698 
BDNF expression in the hippocampus is not associated with a depressive-like 699 
phenotype (Taliaz et al., 2010), but with the OBX-depressive behaviour (Hendriksen et 700 
al., 2012) in rats. Nonetheless, anhedonia and increased levels of BDNF observed in 5-701 
HT4R KO mice are consistent with the increased hippocampal BDNF expression in 702 
mice subjected to chronic unpredictable mild stress (Boulle et al., 2014) and OBX 703 
(Hellweg et al., 2007).  704 
This is the first time in which Arc signalling is studied in OBX animals chronically 705 
treated with fluoxetine, and the literature on this topic is quite controversial (reviewed in 706 
Li et al., 2015). For instance, low levels of Arc mRNA were reported in the frontal 707 
cortex and the hippocampus following chronic social isolation stress in mice (Ieraci et 708 
al., 2016), but increased levels were found in rats following social defeat (Coppens et 709 
al., 2011) and in mice subjected to chronic unpredictable mild stress (Boulle et al., 710 
2014). Pharmacological studies have reported that chronic SSRI treatment stimulates 711 
Arc mRNA expression in the cingulate and orbital frontal cortices in rats without 712 
producing any change in the hippocampus (De Foubert et al., 2004), and that chronic 713 
treatment with agomelatine normalized CUMS-induced increases in the levels of Arc 714 
mRNA in the hippocampus (Boulle et al., 2014). It can be speculated that the increased 715 
levels in Arc mRNA due to the absence of 5-HT4Rs could represent a compensatory 716 
mechanism for the lifelong loss of 5-HT4Rs. It has been reported that 5-HT4R KO mice 717 
exhibit an increased muscarinic neurotransmission (Segu et al., 2010), which may 718 
account for the increased levels of Arc (and BDNF). Indeed, a direct relationship 719 
between cholinergic transmission and these neuroplasticity proteins has been reported 720 
regarding spatial memory acquisition (Gil-Bea et al., 2011).  721 
In conclusion, our study shows that the absence of 5-HT4Rs modulates the response of 722 
mice in depression- and anxiety-like experimental paradigms and did not influence the 723 
behavioural effects of chronic fluoxetine treatment. However, fluoxetine failed to 724 
reverse OBX-induced syndrome in 5-HT4R KO mice, a response classically associated 725 
with differential effects in hippocampal neuroplasticity biomarkers. These results 726 
demonstrate that the absence of 5-HT4Rs triggers adaptive changes that could maintain 727 
a global adaptive emotional state with the exception of anhedonia and a context-728 
dependent anxiety. These findings further unmask that the behavioural and molecular 729 
effects of fluoxetine under pathological depression appear to be critically dependent on 730 
5-HT4Rs. 731 
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SUPPLEMENTARY MATERIAL  1031 
1. METHODS 1032 
1.1. 5-HT4 receptor stimulated adenylate cyclase assay 1033 
5-HT4 receptor stimulated adenylate cyclase assays were carried out as previously 1034 
described by Vidal with slight modifications (Vidal et al., 2009). Striatal tissue samples 1035 
were homogenised (1:120 w/v) in 20 mM Tris-HCl, 2 mM EGTA, 5 mM EDTA, 320 1036 
mM sucrose, 1 mM dithiothreitol (DTT), 25 µg/mL leupeptin, pH 7.4 and centrifuged at 1037 
500xg for 5 min at 4°C. The supernatants were centrifuged at 13000xg for 15 min at 1038 
4°C and the pellets were resuspended in 20 mM Tris-HCl, 1.2 mM EGTA, 0.25 M 1039 
sucrose, 6 mM MgCl2, 3 mM DTT and 25 µg/mL leupeptin. Membrane homogenates 1040 
were pre-incubated for 5 min at 37ºC in reaction buffer (75 mM Tris-HCl pH 7.4, 5 mM 1041 
MgCl2, 0.3 mM EGTA, 60 mM sucrose, 1 mM DTT, 0.5 mM 3-1042 
isobutylmethylxanthine, 5 mM phosphocreatine, 50 U/mL creatine phosphokinase and 5 1043 
U/mL myokinase) and 25 µl of either water (basal activity) or the 5-HT4 agonists 1044 
zacopride (10 µM). The reaction was started by the addition of 0.2 mM Mg-ATP and 1045 
incubated at 37°C for 10 min. The reaction was stopped by boiling the samples for 4 1046 
min and then centrifuged at 13000xg for 5 min at 4°C. cAMP accumulation was 1047 
quantified using a Cyclic AMP Competitive ELISA Kit (Thermo Fisher Scientific, MA, 1048 
USA). Membrane protein concentrations were determined using the Bio-Rad Protein 1049 
Assay Kit (Bio-Rad, Munich, Germany) using γ-globulin as standard. 1050 
1.2. Behavioural tests 1051 
The open-field test was performed as previously described (Linge et al., 2013 and 1052 
2016). The apparatus consisted in a wooden box (50 cm x 50 cm x 30 cm) with the 1053 
centre of the arena highly illuminated (400 lux). Mice were placed in a corner of the 1054 
open-field and allowed to freely explore it for 5 min. Mice behaviour was automatically 1055 
video-tracked and analysed using the Any-maze software (Stoelting Co., USA). The 1056 
total distance travelled, distance travelled in the periphery, time spent in the central 1057 
zone, and distance travelled in the central zone were measured. 1058 
The light-dark box test was performed as previously described by Clément (Clément et 1059 
al., 2009). The apparatus consisted of a shuttle box were the chambers (40 cm x 20 cm x 1060 
35 cm) were separated by a small door. One chamber was illuminated with a high 1061 
intensity light (400 lux) whereas the other was dark. Mice were individually placed on 1062 
the dark side. The time and number of entries into each zone were recorded (Any-maze 1063 
software). 1064 
The sucrose intake test was performed as previously described by Linge (Linge et al., 1065 
2013). Mice were deprived of any drink solution for 24 hours and subsequently each 1066 
animal was given free access to a sucrose solution (1%) for 1 hour. The volume (ml) 1067 
consumed by each animal were measured.  1068 
The forced swimming test (FST) was performed as previously (Porsolt et al., 1977). 1069 
The mice were individually placed in a glass cylinder (height 24 cm, internal diameter 1070 
12 cm) filled with water at 25°C. The mice were left in the cylinder and the immobility 1071 
time during the last four minutes of a 6 min session was measured (Any-maze 1072 
software). Immobility time was considered when mice were floating and with minimal 1073 
movements to keep the head outside the water. Climbing time was considered when 1074 
mice produce active vigorous movements with the forepaws in and out of the water, and 1075 
swimming time was considered when mice produce movement usually horizontal 1076 
throughout the glass cylinder. Three behaviours were manually scored by a trained 1077 
observer in blind conditions using the videotaped FST sessions. 1078 
The novelty suppressed feeding (NSF) was performed as previously described (Linge 1079 
et al., 2013). Briefly, the mice were food-deprived 24 hours and only water was 1080 
available. The day of the experiment, each mouse was placed into an open-field (50 cm 1081 
x 50 cm x 30 cm; luminance 40-50 lux) containing a wood chip bedding with a food 1082 
pellet (2 g) placed in the centre. The latency (in seconds) to eat the pellet was recorded 1083 
(maximum 10 min) with the aid of Any-maze Video-tracking software Stoeling Co., 1084 
USA. Immediately after an eating event, the mouse was placed into the home cage and 1085 
allowed to feed freely for 5 minutes, and the amount of food consumption was 1086 
measured (food consumption post-test). 1087 
The nesting test was adapted from Deacon (Deacon, 2006). In the test day, mice were 1088 
individually housed and a 5 cm square of cotton were placed in every cage at the 1089 
beginning of dark phase. After 12 hours, the nest score was evaluated by using the rate 1090 
scale ranged between 1 and 5 where a score of 1 represents intact cotton or no nest 1091 
produced, and 5 score is a perfect nest.  1092 
1.3. In vitro experiments 1093 
In situ hybridization. The protocol was adapted from Castro (Castro et al., 2003a). 1094 
Cryostat sections were thaw-mounted onto slides and pre-treated for in-situ 1095 
hybridization. Oligonucleotides complementary to BDNF mRNAs 5'-1096 
GGTCTCGTAGAAATATTGGTTCAGTTGGCCTTTTGATACCGGGAC-3' (Vaidya 1097 
et al., 2001) and trkB mRNAs 5´-1098 
CCTTTCATGCCAAACTTGGAATGTCTCGCCAACTTG- 3’ (Madhav et al., 2001) 1099 
and Arc 5’-GCAGCTTCAGGAGAAGAGAGGATGGTGCTGGTGCTGG-3’ (Kelly et 1100 
al., 2008), were 3´end-labelled with [35S]dATP using terminal deoxynucleotide 1101 
transferase and added 250000 c.p.m./slide, with hybridization buffer (50% deionized 1102 
formamide, 4x standard saline citrate (SSC), sodium phospate 10 mM pH 7.0, sodium 1103 
pyrophosphate 1 mM, 10% dextran sulphate, 5x Denhardt’s solution, 200 μg/ml salmon 1104 
sperm DNA, 100 μg/ml poly A, heparin 0.12 mg/ml and 20 mM dithiothreitol). After 1105 
incubation at 42°C for 16 hours, slides were washed at 50°C in 2x SSC buffer with DTT 1106 
1 M twice for 30 minutes followed by three washes of 5 minutes at room temperature 1107 
with 1x SSC, 0.1x SSC, and ethanol 80% consecutively. Finally, slides were washed in 1108 
ethanol 96% for 1 minute at room temperature. Sections were air-dried and exposed to 1109 
film BioMax MR (Carestream) together with 14C microscales at -20oC for 3 weeks. The 1110 
control of specificity was done with the probe without labelling (at a concentration 1000 1111 
times higher). The abundance of mRNA in selected areas was analysed and quantified 1112 
using Scion Image Software. Optical density values were calibrated using 14C 1113 
microscales.  1114 
Autoradiography of protein G coupled to 5-HT1A receptors. Labelling of brain 1115 
sections with [35S]GTPγS was carried out as described previously (Castro et al., 2003b). 1116 
Slide-mounted sections were pre-incubated for 30 min at room temperature in a buffer 1117 
containing 50 mM Tris-HCl, 0.2 mM EGTA, 3 mM MgCl2, 100 mM NaCl, 1 mM dl-1118 
dithiothreitol and 2 mM GDP at pH 7.7. Slides were subsequently incubated, for 2 h, in 1119 
the same buffer containing adenosine deaminase (3 mU/ml) with [35S]GTPγS (0.04 nM) 1120 
and consecutive sections were co-incubated with 8-OH-DPAT (10 µM). The non-1121 
specific binding was determined in the presence of 10 μM guanosine-5-O-(3-thio) 1122 
triphosphate (GTPγS). After the incubation, the sections were washed twice for 15 min 1123 
in cold 50 mM Tris-HCl buffer (pH 7.4) at 4°C, rinsed in distilled cold water and then 1124 
dried under a cold air stream. Sections were exposed to film BioMax MR (Carestream) 1125 
together with 14C microscales at 4oC for 2 days. Selected areas were analysed and 1126 
quantified using Scion Image Software. Optical density values were calibrated using 14C 1127 
microscales.  1128 
BrdU Immunohytochemistry. BrdU staining was performed as previously described 1129 
(Mostany et al., 2008). Free floating coronal sections were incubated for 2 h in 50% 1130 
formamide/2x SSC at 65°C, followed by incubation in 2N HCl for 30 min. Then 1131 
sections were incubated for 10 min in 0.1M borate buffer. After washing in PBS, 1132 
sections were incubated in 1% H2O2 in PBS for 30 min to inactive endogenous 1133 
peroxidase activity. After several rinses in PBS, sections were incubated in PBS/0.2% 1134 
Triton X-100/5% goat serum (PBS-TS) for 30 min and then incubated with monoclonal 1135 
mouse anti-BrdU (1:600; ref.: 11170376001 Roche Diagnostics, Barcelona, Spain) 1136 
overnight at 4°C. After several rinses in PBS-TS, sections were incubated for 2 h with 1137 
biotinylated goat anti-mouse Fab Fragment IgG secondary antibody (1:200; ref.: 115-1138 
066-006 Jackson ImmunoResearch Laboratories, Inc., US-PA), followed by 1139 
amplification with avidin-biotin complex (Vector Laboratories). For quantification of 1140 
BrdU+ cells, one every sixth section throughout the hippocampus was processed and 1141 
counted under a light microscope (Carl Zeiss Axioskop 2 Plus) at 40x and 100x 1142 
magnification. The total number of BrdU+ cells per section were determined and 1143 
multiplied by 6 to obtain the total number of BrdU+ cells per hippocampus.  1144 
 1145 
2. RESULTS 1146 
2.1. Lack of 5-HT4 receptor stimulated adenylate activity in 5-HT4R KO mice 1147 
cAMP basal values in striatal membranes were similar in both genotypes (17.1 ± 1.7 vs 1148 
19.0 ± 1.9 pmol/min/mg protein for WT and 5-HT4R KO mice, respectively). The 5-1149 
HT4 agonist zacopride did not produce any change in 5-HT4 receptor-induced cAMP 1150 
accumulation in 5-HT4R KO mice, (98.8 ± 15.1% zacopride-induced stimulation vs 1151 
100.0 ± 8.1% basal values) compared to the increase observed in WT mice (175.7 ± 1152 
26.7% zacopride-induced cAMP accumulation vs 100.0 ± 2.9% basal values; *p < 1153 
0.05), confirming the lack of 5-HT4 receptors in these KO mice. 1154 
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Figure S1. Absence of cAMP accumulation induced by zacopride (10 µM) in the 1167 
striatum of 5-HT4R KO mice. Two-way ANOVA analysis revealed main effect of 1168 
genotype (F(1,23) = 6.8, p < 0.05), zacopride  (F(1,23) = 6.4, p < 0.05) and genotype x 1169 
zacopride interaction (F(1,23) = 7.1, p < 0.05). **p < 0.001 vs WT- basal and #p < 0.05 1170 
WT-zacopride. Data are mean ± SEM, considering 100% the basal values, of duplicates 1171 
from n = 5-7 mice per group. 1172 
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Figure S2. Behavioural testing schedule. OF: open-field; LDB: light-dark box; NSF: 1174 
novelty-suppressed feeding; Suc: sucrose intake; Nest: nesting test; FST: forced 1175 
swimming test; OBX surgery: olfactory bulbectomy surgery.  1176 
 1177 
Figure S3. Temporal course of the total distance travelled in the open-field. Total 1178 
distance travelled per one minute interval during a 5 min session, before (A) and at 4 1179 
weeks after OBX_surgery (B), in WT and 5-HT4R KO mice. Data are mean ± SEM of n 1180 
= 13-18 mice/group (A), and n = 7-8 mice/group (B).  1181 
 1182 
Figure S4. Effect of olfactory bulbectomy in peripheral and central activity in the 1183 
open-field. Distance travelled at the periphery (A) % of distance travelled in the center 1184 
(B), and number of entries in the central zone (C) in the open-field (5 min sesion) 1185 
following 4 weeks of sham- and OBX surgery. Data are mean ± SEM of n = 7-8 mice 1186 
per group. Two-way ANOVA revealed main effect of the surgery (F(1,26) = 18.0, p < 1187 
0.001), (F(1,26) = 59.4, p < 0.001), (F(1,26) = 42.0, p < 0.001) on A,B and C respectively. 1188 
*p < 0.05, **p < 0.01 and ***p < 0.001 (Newman-Keuls post hoc test). 1189 
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Table S1. Statistical analysis report  
Measurement Statistical test  Comparison Statistics  
Degrees of 
freedom  p Fig. 
Central time 
OF 
Two-way ANOVA 
Treatment (F1) F= 23.2 1, 58 < 0.001 
1A 
Genotype (F2) F= 5.9 1, 58 < 0.05 
Interaction 
(F1xF2) F= 0.1 1, 58 ns 
Newman-Keuls 
multiple comparison 
test 
WT vs KO     < 0.05 
WT vs WT-flx     < 0.01 
KO vs KO-flx     < 0.01 
Number 
central 
entries OF 
Two-way ANOVA 
Treatment (F1) F= 34.2 1, 58 < 0.001 
1B 
Genotype (F2) F= 5.1 1, 58 <0.05 
Interaction 
(F1xF2) F= 0.00 1, 58 ns 
Dunn's multiple 
comparison test 
WT vs WT-flx     < 0.01 
KO vs KO-flx     < 0.05 
Total 
distance 
travelled OF 
Two-way ANOVA 
Treatment (F1) F= 9.0 1, 56 < 0.01 
1C 
Genotype (F2) F= 0.2 1, 56 ns 
Interaction 
(F1xF2) F= 0.00 1, 56 ns 
Newman-Keuls 
multiple comparison 
test 
WT vs KO     ns 
WT vs WT-flx     ns 
KO vs KO-flx     ns 
Time in light 
zone LDB 
Two-way ANOVA 
Treatment (F1) F= 0.02 1, 50 ns 
1D 
Genotype (F2) F= 0.00 1, 50 ns 
Interaction 
(F1xF2) F= 0.2 1, 50 ns 
Newman-Keuls 
multiple comparison 
test 
WT vs KO     ns 
WT vs WT-flx     ns 
KO vs KO-flx     ns 
Latency to 
feeding NSF 
Two-way ANOVA 
Treatment (F1) F= 14.4 1, 50 < 0.001 
1E 
Genotype (F2) F= 0.4 1, 50 ns 
Interaction 
(F1xF2) F= 0.00 1, 50 ns 
Newman-Keuls 
multiple comparison 
test 
WT vs KO     ns 
WT vs WT-flx     < 0.05 
KO vs KO-flx     < 0.05 
Post test NSF 
Two-way ANOVA 
Treatment (F1) F= 0.2 1, 52 ns 
1F 
Genotype (F2) F= 0.2 1, 52 ns 
Interaction 
(F1xF2) F= 0.09 1, 52 ns 
Newman-Keuls 
multiple comparison 
test 
WT vs KO     ns 
WT vs WT-flx     ns 
KO vs KO-flx     ns 
 
  
Measurement Statistical test  Comparison Statistics  
Degrees of 
freedom  p Fig. 
Sucrose 
intake  
Two-way ANOVA 
Treatment (F1) F= 22.7 1, 60 < 0.001 
2A 
Genotype (F2) F= 3.5 1, 60 ns 
Interaction 
(F1xF2) F= 9.5 1, 60 < 0.01 
Newman-Keuls 
multiple comparison 
test 
WT vs KO     < 0.001 
WT vs WT-flx     ns 
KO vs KO-flx     < 0.01 
Nesting test  
Two-way ANOVA 
Treatment (F1) F= 1.4 1, 63 ns 
2B 
Genotype (F2) F= 4.4 1, 63 < 0.05 
Interaction 
(F1xF2) F= 3.2 1, 63 ns 
Dunn's multiple 
comparison test 
WT vs KO     < 0.05 
WT vs WT-flx     ns 
KO vs KO-flx     ns 
Immobility 
time FST  
Two-way ANOVA 
Treatment (F1) F= 21.6 1, 51 < 0.001 
2C 
Genotype (F2) F= 0.2 1, 51 ns 
Interaction 
(F1xF2) F= 0.09 1, 51 ns 
Newman-Keuls 
multiple comparison 
test 
WT vs KO     ns 
WT vs WT-flx     < 0.01 
KO vs KO-flx     < 0.01 
Swimming 
time FST  
Two-way ANOVA 
Treatment (F1) F= 18.3 1, 51 < 0.001 
2D 
Genotype (F2) F= 0.7 1, 51 ns 
Interaction 
(F1xF2) F= 0.3 1, 51 ns 
Newman-Keuls 
multiple comparison 
test 
WT vs KO     ns 
WT vs WT-flx     < 0.05 
KO vs KO-flx     < 0.01 
Climbing 
time FST  
Two-way ANOVA 
Treatment (F1) F= 20.7 1, 50 < 0.001 
2E 
Genotype (F2) F= 1.01 1, 50 ns 
Interaction 
(F1xF2) F= 0.2 1, 50 ns 
Newman-Keuls 
multiple comparison 
test 
WT vs KO     ns 
WT vs WT-flx     < 0.001 
KO vs KO-flx     < 0.05 
 
  
Measurement Statistical test  Comparison Statistics  
Degrees of 
freedom  p Fig. 
8-OH-DPAT 
induced 
hypothermia  
Two-way ANOVA 
Treatment (F1) F= 42.3 1, 19 < 0.001 
3 
Genotype (F2) F= 4.7 1, 19 < 0.05 
Interaction 
(F1xF2) F= 1.9 1, 19 ns 
Newman-Keuls 
multiple comparison 
test 
WT flx PAT  vs 
KO-flx PAT     < 0.05 
WT PAT vs  
WT-flx PAT     < 0.01 
KO PAT vs  
KO-flx PAT     < 0.001 
Specific 
basal  
[35S]GTPγS 
binding Student t- test 
WT vs KO DRN  t= 3.1 1, 12 < 0.01 
4 
Table1 WT vs KO CxF t= 2.9 1, 11 < 0.05 
Specific 8-
OH-DPAT-
induced  
[35S]GTPγS 
binding Student t- test WT vs KO DRN  t= 2.7 1, 12 < 0.05 
4 
Table1 
BDNF Student t- test WT vs KO DG  t= 2.5 1, 11 < 0.05 5A 
TrkB Student t- test  
WT vs KO Amyg  t= 2.8 1, 11 < 0.05 
5B 
WT vs KO CA1  t= 5.4 1, 12 < 0.01 
WT vs KO CA3  t= 2.3 1, 12 < 0.01 
Arc Student t- test  
WT vs KO  
Cx-cing t= 2.6 1, 12 < 0.05 
5C 
WT vs KO CA1  t= 2.7 1, 12 < 0.05 
WT vs KO CA3  t= 2.4 1, 12 < 0.05 
Total 
distance OF 
after surgery 
OBX  
Two-way ANOVA 
surgery (F1) F= 9.4 1, 26 < 0.01 
6A 
genotype (F2) F= 0.3 1, 26 < 0.05 
interaction 
(F1xF2) F= 0.1 1, 26 ns 
Newman-Keuls 
multiple comparison 
test 
WT -sham vs 
WT-OBX     < 0.05 
KO-sham vs  
KO-OBX     < 0.05 
Time in the 
center of  OF 
after surgery 
OBX  
Two-way ANOVA 
Surgery (F1) F= 35.04 1, 26 < 0.001 
6B 
Genotype (F2) F= 0.08 1, 26 ns 
Interaction 
(F1xF2) F= 0.9 1, 26 ns 
Newman-Keuls 
multiple comparison 
test 
WT -sham vs 
WT-OBX     < 0.001 
KO-sham vs  
KO-OBX     < 0.001 
 
  
Measurement Statistical test  Comparison Statistics  
Degrees of 
freedom  p Fig. 
Peripheral 
distance   OF 
fluoxetine 
treatment   
Two-way ANOVA 
Time (F1) F= 22.0 1, 26 < 0.001 
7A 
Genotype (F2) F= 1.5 1, 26 ns 
Interaction 
(F1xF2) F= 7.1 1, 26 < 0.01 
Newman-Keuls 
multiple comparison 
test 
WT-OBX vs 
WT-OBX flx 28d     < 0.05 
Peripheral 
distance per 
minute   OF 
fluoxetine 
treatment   
Two-way ANOVA 
Time (F1) F= 4.7 4, 52 < 0.01 
7B  
Genotype (F2) F= 6.6 1, 52 < 0.05 
Interaction 
(F1xF2) F= 1.2 4, 52 ns 
Newman-Keuls 
multiple comparison 
test 
KO-OBX flx 28d 
1' vs KO-OBX flx 
28d 5'     < 0.01 
KO-OBX flx 28d 
1' vs KO-OBX flx 
28d 4'     < 0.01 
KO-OBX flx 28d 
1' vs KO-OBX flx 
28d 3'     < 0.05 
KO-OBX flx 28d 
1' vs KO-OBX flx 
28d 2'     < 0.05 
 
 
 
 
Measurement Statistical test  Comparison Statistics  
Degrees of 
freedom  p Fig. 
BDNF 
expression in 
DG 
Two-way ANOVA 
Treatment (F1) F= 16.1 1, 30 < 0.001 
8A 
Genotype (F2) F= 1.3 1, 30 ns 
Interaction 
(F1xF2) F= 1.3 1, 30 ns 
Newman-Keuls 
multiple comparison 
test 
WT-OBX vs 
WT-OBX flx 28d     < 0.05 
KO-OBX vs  
KO-OBX flx 28d     ns 
BDNF 
expression in 
CA3 Two-way ANOVA 
Treatment (F1) F= 14.0 1, 31 < 0.001 
8B 
Genotype (F2) F= 5.7 1, 31 < 0.05 
Interaction 
(F1xF2) F= 0.7 1, 31 ns 
Newman-Keuls 
multiple comparison 
test 
WT-OBX vs 
WT-OBX flx 28d     < 0.05 
KO-OBX vs  
KO-OBX flx 28d     ns 
BDNF 
expression in 
CA1 
Two-way ANOVA 
Treatment (F1) F= 14.9 1, 32 < 0.001 
8C 
Genotype (F2) F= 0.6 1, 32 ns 
Interaction 
(F1xF2) F= 0.01 1, 32 ns 
Newman-Keuls 
multiple comparison 
test 
WT-OBX vs 
WT-OBX flx 28d     < 0.05 
KO-OBX vs  
KO-OBX flx 28d     < 0.05 
Arc 
expression in 
DG 
Two-way ANOVA 
Treatment (F1) F= 14.3 1, 30 < 0.001 
8D 
Genotype (F2) F= 2.4 1, 30 ns 
Interaction 
(F1xF2) F= 0.01 1, 30 ns 
Newman-Keuls 
multiple comparison 
test 
WT-OBX vs 
WT-OBX flx 28d     < 0.05 
KO-OBX vs  
KO-OBX flx 28d     < 0.05 
Arc 
expression in 
CA3 
Two-way ANOVA 
Treatment (F1) F= 16.5 1, 30 < 0.001 
8E 
Genotype (F2) F= 11.7 1, 30 <0.01 
Interaction 
(F1xF2) F= 0.5 1, 30 ns 
Newman-Keuls 
multiple comparison 
test 
WT-OBX vs 
WT-OBX flx 28d     < 0.05 
KO-OBX vs  
KO-OBX flx 28d     < 0.05 
Arc 
expression in 
CA1 
Two-way ANOVA 
Treatment (F1) F= 13.9 1, 31 < 0.001 
8F 
Genotype (F2) F= 5.9 1, 31 < 0.05 
Interaction 
(F1xF2) F= 1.7 1, 31 ns 
Newman-Keuls 
multiple comparison 
test 
WT-OBX vs 
WT-OBX flx 28d     < 0.01 
WT-OBX flx 28d 
vs KO-OBX flx 
28d      < 0.05 
 
  
Measurement Statistical test  Comparison Statistics  
Degrees of 
freedom  p Fig. 
cAMP 
acumulation 
induced by 
Zacopride 
Two-way ANOVA 
Treatment (F1) F= 6.4 1, 23 < 0.05 
S1 
Genotype (F2) F= 6.8 1, 23 < 0.05 
Interaction 
(F1xF2) F= 7.1 1, 23 < 0.05 
Newman-Keuls 
multiple comparison 
test 
WT-basal vs WT-
zacopride     < 0.01 
WT-zacopride vs 
KO-zacopride     < 0.05 
Total 
distance per 
minute OF   
Two-way repeated 
measures ANOVA  
Time (F1) F= 9.7   < 0.001 
S3A 
Genotype (F2) F= 0.03   ns 
Interaction 
(F1xF2) F= 0.9   ns 
Total 
distance per 
minute after 
OB surgery 
in  OF   
Two-way repeated 
measures ANOVA  
Time (F1) F= 0.5   ns 
S3B 
Genotype (F2) F= 0.4   ns 
Interaction 
(F1xF2) F= 0.3   ns 
Peripheral 
distance in 
the OF after 
OBX surgery 
Two-way ANOVA 
Surgery (F1) F= 18 1, 26 < 0.001 
S4A 
Genotype (F2) F= 0.3 1, 26 ns 
Interaction 
(F1xF2) F= 0.00 1, 26 ns 
Newman-Keuls 
multiple comparison 
test 
WT-sham vs  
WT-OBX      < 0.05 
KO-sham vs  
KO-OBX      < 0.01 
% central 
distance in 
the OF after 
OBX surgery 
Two-way ANOVA 
Surgery (F1) F= 59.4 1, 26 < 0.001 
S4B 
Genotype (F2) F= 0.3 1, 26 ns 
Interaction 
(F1xF2) F= 0.01 1, 26 ns 
Newman-Keuls 
multiple comparison 
test 
WT-sham vs  
WT-OBX      < 0.001 
KO-sham vs  
KO-OBX      < 0.001 
Number of 
entries in the 
OF after 
OBX surgery 
Two-way ANOVA 
Surgery (F1) F= 42.0 1, 26 < 0.001 
S4C 
Genotype (F2) F= 0.01 1, 26 ns 
Interaction 
(F1xF2) F= 0.06 1, 26 ns 
Newman-Keuls 
multiple comparison 
test 
WT-sham vs  
WT-OBX      < 0.05 
KO-sham vs  
KO-OBX      < 0.001 
 
 
